Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Acta Angiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Publisher's Jubilee Conference Abstracts Reviewers 2022

open access

Vol 14, No 4 (2008)
Review paper
Published online: 2008-12-19
View PDF (Polish) Download PDF file
Get Citation

Cardiovascular gene therapy: an application of HIF-1α gene

Maciej Małecki, Robert Proczka, Beata Chmiel, Agnieszka Kotlarz, Joanna Chorostowska-Wynimko
Acta Angiologica 2008;14(4):125-130.

open access

Vol 14, No 4 (2008)
Review papers
Published online: 2008-12-19

Abstract

Currently gene therapy is mostly focused on cancer treatment trials, cardiovascular and infectious diseases. Nowadays gene therapy for cardiovascular diseases is recognised thanks to successful clinical trials that have used mainly genes encoding proangiogenic citokines,eg vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatic growth factor (HGF). Progress in gene therapy of cardiovascular diseases needs not only basic studies for “new” genes, but also needs good prepeared clinical trials. Hipoxia inducible factor (HIF-1) is a physiological regulator of processes related to angiogenesis with a potential therapeutic meaning. A protein encoded by HIF-1a activates groups of genes responsible for preservation of oxygen homeostasis, activation of angiogenesis, erythropoiesis, regulation of glucose metabolism. There are known preliminary studies describing that gene HIF-1a is used in therapy of cardiovascular diseases. Animal trials and first clinic tests point out that administration of gene preparation HIF-1a efficiently induces neovascularization in ischemic tissues . Further research will indicate if gene HIF will be useful in treating cardiovascular diseases and if yes then in what period of time we will get such a result.

Abstract

Currently gene therapy is mostly focused on cancer treatment trials, cardiovascular and infectious diseases. Nowadays gene therapy for cardiovascular diseases is recognised thanks to successful clinical trials that have used mainly genes encoding proangiogenic citokines,eg vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatic growth factor (HGF). Progress in gene therapy of cardiovascular diseases needs not only basic studies for “new” genes, but also needs good prepeared clinical trials. Hipoxia inducible factor (HIF-1) is a physiological regulator of processes related to angiogenesis with a potential therapeutic meaning. A protein encoded by HIF-1a activates groups of genes responsible for preservation of oxygen homeostasis, activation of angiogenesis, erythropoiesis, regulation of glucose metabolism. There are known preliminary studies describing that gene HIF-1a is used in therapy of cardiovascular diseases. Animal trials and first clinic tests point out that administration of gene preparation HIF-1a efficiently induces neovascularization in ischemic tissues . Further research will indicate if gene HIF will be useful in treating cardiovascular diseases and if yes then in what period of time we will get such a result.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

gene therapy; gene preparations; hipoxia; cardiovascular diseases

About this article
Title

Cardiovascular gene therapy: an application of HIF-1α gene

Journal

Acta Angiologica

Issue

Vol 14, No 4 (2008)

Article type

Review paper

Pages

125-130

Published online

2008-12-19

Page views

738

Article views/downloads

1761

Bibliographic record

Acta Angiologica 2008;14(4):125-130.

Keywords

gene therapy
gene preparations
hipoxia
cardiovascular diseases

Authors

Maciej Małecki
Robert Proczka
Beata Chmiel
Agnieszka Kotlarz
Joanna Chorostowska-Wynimko

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl